Systemic therapy of acne in teenagers

Abstract

The goal was to determine clinical and anamnestic features of acne patients aged up to 18 years needing systemic isotretinoin treatment, and to assess the treatment dynamics. Materials and methods. The authors conducted a study of 27 patients with moderate to severe acne (with the mean age of 16.2 ± 1.2 years) receiving isotretinoin in the form of LIDOSE (Acnecutan) in the dose of 0.33 ± 0.06 mg/kg. Results. A steady improvement of the skin condition was observed when the dose of isotretinoin in the form of LIDOSE of 60.3 ± 2.8 mg/kg was used. Clinical recovery was observed in all of the patients (the cumulative dose amounted to 100 mg/kg). Teenagers demonstrated good tolerance to the drug and had no systemic adverse effects.